REC Interventional Cardiology最新文献

Introduction and objectives: Calcified coronary lesions are becoming more prevalent and remain therapeutically challenging. Although a variety of devices can be used in this setting, cutting balloons (CB) and scoring balloons (SB) are powerful and simple tools to treat calcified plaques vs more complex devices. However, there are some drawbacks: these are stiff and bulky balloons that, as a first device, complicate lesion crossing and navigability in the presence of tortuosity, thus making it extremely difficult to recross once the balloon has been inflated. The objective of this study was to evaluate the safety and efficacy profile of the new Naviscore SB designed to overcome these drawbacks.

Methods: The first-in-man Naviscore Registry is a multicenter, prospective trial that included 85 patients with moderate (34%) or severe (66%) de novo calcified coronary lesions located in the native arteries, with stable angina and an indication for percutaneous coronary intervention.

Results: Mean age was 71 ± 11 years, with a high prevalence of comorbidities. Used as the first device, the Naviscore was able to cross 76% of the lesions and was used in 98% of the cases effectively modifying the calcified plaque. Procedural success was achieved in 94% of cases. Basal stenosis of 81 ± 12% decreased to 33 ± 8.5% after Naviscore and to 7.5 ± 2.6% after stent implantation. There were no major adverse cardiovascular events during admission. Perforation, device entrapment or flow-limiting dissections did not occur-only type A/B dissections in 13%-which were fixed with stent implantation. Device performance was deemed superior to the usual SB or CB used by the participant centers.

Conclusions: The Naviscore SB is very effective crossing severely calcified lesions as the first device, with effective plaque modification, stent expansion and an excellent safety profile. The Naviscore improves the behavior of current CB and SB. Due to its simplicity of use and performance, the Naviscore can be the first-choice SB to treat significant calcified lesions.

Introduction and objectives: The use of coronary physiology is essential to guide revascularization in patients with stable coronary artery disease. However, some patients without significant angiographic coronary artery disease will experience cardiovascular events at the follow-up. This study aims to determine the prognostic value of the global plaque volume (GPV) in patients with stable coronary artery disease without functionally significant lesions at a 5-year follow-up.

Methods: We conducted a multicenter, observational, and retrospective cohort study with a 5-year follow-up. A total of 277 patients without significant coronary artery disease treated with coronary angiography in 2015 due to suspected stable coronary artery disease were included in the study. The 3 coronary territories were assessed using quantitative flow ratio, calculating the GPV by determining the difference between the luminal volume and the vessel theoretical reference volume.

Results: The mean GPV was 170.5 mm³. A total of 116 patients (42.7%) experienced major adverse cardiovascular events (MACE) at the follow-up, including cardiac death (11%), myocardial infarction (2.6%), and unexpected hospital admissions (38.1%). Patients with MACE had a significantly higher GPV (231.6 mm³ vs 111.8 mm³; P < .001). The optimal GPV cut-off point for predicting events was 44 mm³. Furthermore, in the multivariate analysis conducted, plaque volume, diabetes, hypertension, age, dyslipidemia, smoking, age, and GPV > 44 mm³ turned out to be independent predictors of MACE.

Conclusions: GPV, calculated from the three-dimensional reconstruction of the coronary tree, is an independent predictor of events in patients with stable coronary artery disease without significant lesions. A GPV > 44 mm³ is an optimal cut-off point for predicting events.

Introduction and objectives: There is limited data on the impact of the culprit vessel on very long-term outcomes after ST-elevation myocardial infarction (STEMI). The aim was to analyze the impact of the left anterior descending coronary artery (LAD) as the culprit vessel of STEMI on very long-term outcomes.

Methods: We analyzed patients included in the EXAMINATION-EXTEND study (NCT04462315) treated with everolimus-eluting stents or bare-metal stents after STEMI (1498 patients) and stratified according to the culprit vessel (LAD vs other vessels). The primary endpoint was the patient-oriented composite endpoint (POCE), including all-cause mortality, myocardial infarction (MI) or revascularization at 10 years. Secondary endpoints were individual components of POCE, device-oriented composite endpoint and its individual components and stent thrombosis. We performed landmark analyses at 1 and 5 years. All endpoints were adjusted with multivariable Cox regression models.

Results: The LAD was the culprit vessel in 631 (42%) out of 1498 patients. The LAD-STEMI group had more smokers, advanced Killip class and worse left ventricular ejection fraction. Conversely, non-LAD-STEMI group showed more peripheral vascular disease, previous MI, or previous PCI. At 10 years, no differences were observed between groups regarding POCE (34.9% vs 35.4%; adjusted hazard ratio [HR], 0.95; 95% confidence interval [95%CI], 0.79-1.13; P = .56) or other endpoints. The all-cause mortality rate was higher in the LAD-STEMI group (P = .041) at 1-year.

Conclusions: In a contemporary cohort of STEMI patients, there were no differences in POCE between LAD as the STEMI-related culprit vessel and other vessels at 10 years follow-up. However, all-cause mortality was more common in the LAD-STEMI group within the first year after STEMI.